Imaging of liver cancer

World Journal of Gastroenterology

Volumn 15, Issue 11, 2009, Pages 1289-1300

  Ariff, Ben ^a   Lloyd, Claire R ^a   Khan, Sameer ^a   Shariff, Mohamed ^b   Thillainayagan, Andrew V ^b   Bansi, Devinder S ^b   Khan, Shahid A ^b   Taylor Robinson, Simon D ^b   Lim, Adrian K P ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cholangiocarcinoma; Computed tomography; Contrast enhanced ultrasound; Hepatic cell carcinoma; Magnetic resonance imaging

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GADOBENIC ACID; GADOLINIUM; IODINATED POPPYSEED OIL; SUPERPARAMAGNETIC IRON OXIDE;

B SCAN; BILE DUCT CARCINOMA; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PEROPERATIVE ECHOGRAPHY; POSITRON EMISSION TOMOGRAPHY; REVIEW; ULTRASOUND; ECHOGRAPHY; LIVER CELL; LIVER TUMOR; METASTASIS; METHODOLOGY; PATHOLOGY; RADIOGRAPHY;

CHOLANGIOCARCINOMA; CONTRAST MEDIA; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM METASTASIS; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 65649093283     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.1289     Document Type: Review

References (103)

1. Vauthey JN, Klimstra D, Blumgart LH. A simplified staging system for hepatocellular carcinomas. Gastroenterology 1995; 108: 617-618
2. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271-285
3. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994; 14: 109-114
4. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008; 10: 77-82
5. Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52 Suppl 3: iii1-iii8
6. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51 Suppl 6: VI1-VI9
7. Cosgrove DO, Eckersley R. Contrast-enhanced ultrasound: Basic physics and technology overview. In: Lencioni R. Enhancing the role of ultrasound with ultrasound contrast agents. Pisa: Springer, 2006: 3-14
8. Kono Y, Steinbach GC, Peterson T, Schmid-Schonbein GW, Mattrey RF. Mechanism of parenchymal enhancement of the liver with a microbubble-based US contrast medium: an intravital microscopy study in rats. Radiology 2002; 224: 253-257
9. Yanagisawa K, Moriyasu F, Miyahara T, Yuki M, Iijima H. Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol 2007; 33: 318-325
10. Piscaglia F, Bolondi L. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol 2006; 32: 1369-1375
11. Weg N, Scheer MR, Gabor MP. Liver lesions: improved detection with dual-detector-array CT and routine 2.5-mm thin collimation. Radiology 1998; 209: 417-426
12. Foley WD, Mallisee TA, Hohenwalter MD, Wilson CR, Quiroz FA, Taylor AJ. Multiphase hepatic CT with a multirow detector CT scanner. AJR Am J Roentgenol 2000; 175: 679-685
13. Glockner JF. Hepatobiliary MRI: current concepts and controversies. J Magn Reson Imaging 2007; 25: 681-695
14. Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, Brown JJ, McFarland EG, Middleton WD, Balfe DM, Ritter JH. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003; 226: 533-542
15. Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology 2001; 218: 27-38
16. Bellin MF. MR contrast agents, the old and the new. Eur J Radiol 2006; 60: 314-323
17. Gandhi SN, Brown MA, Wong JG, Aguirre DA, Sirlin CB. MR contrast agents for liver imaging: what, when, how. Radiographics 2006; 26: 1621-1636
18. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007; 242: 647-649
19. Board of the faculty of the Royal College of Radiologists. Gadolinium-based contrast media and nephrogenic systemic sclerosis. 2007. Royal College of Radiology, UK. Available from: URL: http://www.rcr.ac.uk/docs/radiology/pdf/ BFCR0714_Gadolinium_NSF_guidanceNov07.pdf
20. Hamm B, Vogl TJ, Branding G, Schnell B, Taupitz M, Wolf KJ, Lissner J. Focal liver lesions: MR imaging with Mn-DPDP - initial clinical results in 40 patients. Radiology 1992; 182: 167-174
21. Ferrucci JT, Stark DD. Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. AJR Am J Roentgenol 1990; 155: 943-950
22. Ward J, Guthrie JA, Scott DJ, Atchley J, Wilson D, Davies MH, Wyatt JI, Robinson PJ. Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology 2000; 216: 154-162
23. Halavaara J, Tervahartiala P, Isoniemi H, Hockerstedt K. Efficacy of sequential use of superparamagnetic iron oxide and gadolinium in liver MR imaging. Acta Radiol 2002; 43: 180-185
24. Kim YK, Kwak HS, Kim CS, Chung GH, Han YM, Lee JM. Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. Radiology 2006; 238: 531-541
25. Araki T. SPIO-MRI in the detection of hepatocellular carcinoma. J Gastroenterol 2000; 35: 874-876
26. Ward J, Robinson PJ, Guthrie JA, Downing S, Wilson D, Lodge JP, Prasad KR, Toogood GJ, Wyatt JI. Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology 2005; 237: 170-180
27. Chow LC, Bammer R, Moseley ME, Sommer FG. Single breath-hold diffusion-weighted imaging of the abdomen. J Magn Reson Imaging 2003; 18: 377-382
28. Meikle SR, Dahlbom M. Positron emission tomography (PET). In: Ell PJ, Gambhir SS. Nuclear medicine in clinical diagnosis and treatment. Edinburgh: Churchill Livingstone, 2004: 1827-1843
29. Choi BY, Nguyen MH. The diagnosis and management of benign hepatic tumors. J Clin Gastroenterol 2005; 39: 401-412
30. Colombo M. Risk groups and preventive strategies. In: Berr F, Bruix J, Hauss J, Wands J, Wittekind C, editors. Malignant liver tumors: basic concepts and clinical management. Falk symposium: Kluwer Academic Publishers, 2003: 67-74
31. Taura N, Hamasaki K, Nakao K, Ichikawa T, Nishimura D, Goto T, Fukuta M, Kawashimo H, Motoyoshi Y, Shibata H, Eguchi K. Clinical benefits of hepatocellular carcinoma surveillance: a single-center, hospital-based study. Oncol Rep 2005; 14: 999-1003
32. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430
33. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14: 4300-4308
34. Roncalli M, Roz E, Coggi G, Di Rocco MG, Bossi P, Minola E, Gambacorta M, Borzio M. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 1999; 30: 1174-1178
35. Torzilli G, Minagawa M, Takayama T, Inoue K, Hui AM, Kubota K, Ohtomo K, Makuuchi M. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999; 30: 889-893
36. Nicolau C, Bru C. Characterisation of hepatocellular carcinoma in cirrhosis. In: Lencioni R. Enhancing the role of ultrasound with ultrasound contrast agents. Pisa: Springer, 2006: 39-52
37. Nicolau C, Vilana R, Catala V, Bianchi L, Gilabert R, Garcia A, Bru C. Importance of evaluating all vascular phases on contrast-enhanced sonography in the differentiation of benign from malignant focal liver lesions. AJR Am J Roentgenol 2006; 186: 158-167
38. Baron RL, Oliver JH 3rd, Dodd GD 3rd, Nalesnik M, Holbert BL, Carr B. Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. Radiology 1996; 199: 505-511
39. Brancatelli G, Federle MP, Grazioli L, Carr BI. Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 U.S. residents. Radiology 2002; 222: 89-94
40. Iannaccone R, Piacentini F, Murakami T, Paradis V, Belghiti J, Hori M, Kim T, Durand F, Wakasa K, Monden M, Nakamura H, Passariello R, Vilgrain V. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: helical CT and MR imaging findings with clinical-pathologic comparison. Radiology 2007; 243: 422-430
41. Tublin ME, Dodd GD 3rd, Baron RL. Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol 1997; 168: 719-723
42. Itai Y, Moss AA, Goldberg HI. Transient hepatic attenuation difference of lobar or segmental distribution detected by dynamic computed tomography. Radiology 1982; 144: 835-839
43. Brancatelli G, Baron RL, Peterson MS, Marsh W. Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-positive interpretation. AJR Am J Roentgenol 2003; 180: 1007-1014
44. Murakami T, Kim T, Takamura M, Hori M, Takahashi S, Federle MP, Tsuda K, Osuga K, Kawata S, Nakamura H, Kudo M. Hypervascular hepatocellular carcinoma: detection with double arterial phase multi-detector row helical CT. Radiology 2001; 218: 763-767
45. Iannaccone R, Laghi A, Catalano C, Rossi P, Mangiapane F, Murakami T, Hori M, Piacentini F, Nofroni I, Passariello R. Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology 2005; 234: 460-467
46. Bizollon T, Rode A, Bancel B, Gueripel V, Ducerf C, Baulieux J, Trepo C. Diagnostic value and tolerance of Lipiodol-computed tomography for the detection of small hepatocellular carcinoma: correlation with pathologic examination of explanted livers. J Hepatol 1998; 28: 491-496
47. Taourel PG, Pageaux GP, Coste V, Fabre JM, Pradel JA, Ramos J, Larrey D, Domergue J, Michel H, Bruel JM. Small hepatocellular carcinoma in patients undergoing liver transplantation: detection with CT after injection of iodized oil. Radiology 1995; 197: 377-380
48. Beavers KL, Semelka RC. MRI evaluation of the liver. Semin Liver Dis 2001; 21: 161-177
49. Hussain SM, Zondervan PE, IJzermans JN, Schalm SW, de Man RA, Krestin GP. Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. Radiographics 2002; 22: 1023-1036; discussion 1037-1039
50. Ichikawa T, Federle MP, Grazioli L, Madariaga J, Nalesnik M, Marsh W. Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases. Radiology 1999; 213: 352-361
51. Namimoto T, Yamashita Y, Sumi S, Tang Y, Takahashi M. Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging. Radiology 1997; 204: 739-744
52. Nasu K, Kuroki Y, Nawano S, Kuroki S, Tsukamoto T, Yamamoto S, Motoori K, Ueda T. Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 2006; 239: 122-130
53. Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 2003; 226: 71-78
54. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, Zeuzem S. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 3314-3319
55. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, Collins BT, Di Bisceglie AM. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32: 792-797
56. Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003; 44: 213-221
57. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, Donato MF, Piva A, Di Carlo V, Dioguardi N. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-680
58. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology 1986; 6: 729-738
59. Fracanzani AL, Burdick L, Borzio M, Roncalli M, Bonelli N, Borzio F, Maraschi A, Fiorelli G, Fargion S. Contrastenhanced Doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology 2001; 34: 1109-1112
60. Vilana R, Llovet JM, Bianchi L, Sanchez M, Pages M, Sala M, Gilabert R, Nicolau C, Garcia A, Ayuso C, Bruix J, Bru C. Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. J Clin Ultrasound 2003; 31: 119-128
61. Giorgio A, Ferraioli G, Tarantino L, de Stefano G, Scala V, Scarano F, Coppola C, Del Viscovo L. Contrast-enhanced sonographic appearance of hepatocellular carcinoma in patients with cirrhosis: comparison with contrast-enhanced helical CT appearance. AJR Am J Roentgenol 2004; 183: 1319-1326
62. Gaiani S, Celli N, Piscaglia F, Cecilioni L, Losinno F, Giangregorio F, Mancini M, Pini P, Fornari F, Bolondi L. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol 2004; 41: 421-426
63. Peterson MS, Baron RL, Marsh JW Jr, Oliver JH 3rd, Confer SR, Hunt LE. Pretransplantation surveillance for possible hepatocellular carcinoma in patients with cirrhosis: epidemiology and CT-based tumor detection rate in 430 cases with surgical pathologic correlation. Radiology 2000; 217: 743-749
64. Jeong YY, Yim NY, Kang HK. Hepatocellular carcinoma in the cirrhotic liver with helical CT and MRI: imaging spectrum and pitfalls of cirrhosis-related nodules. AJR Am J Roentgenol 2005; 185: 1024-1032
65. Goshima S, Kanematsu M, Matsuo M, Kondo H, Yokoyama R, Hoshi H, Moriyama N. Early-enhancing nonneoplastic lesions on gadolinium-enhanced magnetic resonance imaging of the liver following partial hepatectomy. J Magn Reson Imaging 2004; 20: 66-74
66. Jeong YY, Mitchell DG, Kamishima T. Small (<20 mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications. AJR Am J Roentgenol 2002; 178: 1327-1334
67. Pauleit D, Textor J, Bachmann R, Conrad R, Flacke S, Layer G, Kreft B, Schild H. Hepatocellular carcinoma: detection with gadolinium- and ferumoxides-enhanced MR imaging of the liver. Radiology 2002; 222: 73-80
68. Kondo H, Kanematsu M, Hoshi H, Murakami T, Kim T, Hori M, Matsuo M, Nakamura H. Preoperative detection of malignant hepatic tumors: comparison of combined methods of MR imaging with combined methods of CT. AJR Am J Roentgenol 2000; 174: 947-954
69. Low RN. Abdominal MRI advances in the detection of liver tumours and characterisation. Lancet Oncol 2007; 8: 525-535
70. Neumaier CE, Bertolotto M, Perrone R, Martinoli C, Loria F, Silvestri E. Staging of hilar cholangiocarcinoma with ultrasound. J Clin Ultrasound 1995; 23: 173-178
71. Hann LE, Greatrex KV, Bach AM, Fong Y, Blumgart LH. Cholangiocarcinoma at the hepatic hilus: sonographic findings. AJR Am J Roentgenol 1997; 168: 985-989
72. Saini S. Imaging of the hepatobiliary tract. N Engl J Med 1997; 336: 1889-1894
73. Valls C, Guma A, Puig I, Sanchez A, Andia E, Serrano T, Figueras J. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging 2000; 25: 490-496
74. Lacomis JM, Baron RL, Oliver JH 3rd, Nalesnik MA, Federle MP. Cholangiocarcinoma: delayed CT contrast enhancement patterns. Radiology 1997; 203: 98-104
75. Tillich M, Mischinger HJ, Preisegger KH, Rabl H, Szolar DH. Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma. AJR Am J Roentgenol 1998; 171: 651-658
76. Aloia TA, Charnsangavej C, Faria S, Ribero D, Abdalla EK, Vauthey JN, Curley SA. High-resolution computed tomography accurately predicts resectability in hilar cholangiocarcinoma. Am J Surg 2007; 193: 702-706
77. Baron R, Ferris J. Primary tumours of the liver and biliary tract. In: Husband J, Reznek R, editors. Imaging in oncology. London: Taylor & Francis, 2004: 245-272
78. Ros PR, Buck JL, Goodman ZD, Ros AM, Olmsted WW. Intrahepatic cholangiocarcinoma: radiologic-pathologic correlation. Radiology 1988; 167: 689-693
79. Guthrie JA, Ward J, Robinson PJ. Hilar cholangiocarcinomas: T2-weighted spin-echo and gadolinium-enhanced FLASH MR imaging. Radiology 1996; 201: 347-351
80. Lopera JE, Soto JA, Munera F. Malignant hilar and perihilar biliary obstruction: use of MR cholangiography to define the extent of biliary ductal involvement and plan percutaneous interventions. Radiology 2001; 220: 90-96
81. Romagnuolo J, Bardou M, Rahme E, Joseph L, Reinhold C, Barkun AN. Magnetic resonance cholangiopancreatograph y: a meta-analysis of test performance in suspected biliary disease. Ann Intern Med 2003; 139: 547-557
82. Masselli G, Gualdi G. Hilar cholangiocarcinoma: MRI/MRCP in staging and treatment planning. Abdom Imaging 2008; 33: 444-451
83. Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004; 8: 90-97
84. Fritscher-Ravens A, Bohuslavizki KH, Broering DC, Jenicke L, Schafer H, Buchert R, Rogiers X, Clausen M. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun 2001; 22: 1277-1285
85. Kim YJ, Yun M, Lee WJ, Kim KS, Lee JD. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2003; 30: 1467-1472
86. Prytz H, Keiding S, Bjornsson E, Broome U, Almer S, Castedal M, Munk OL. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 2006; 44: 1572-1580
87. Karhunen PJ. Benign hepatic tumours and tumour like conditions in men. J Clin Pathol 1986; 39: 183-188
88. Jones EC, Chezmar JL, Nelson RC, Bernardino ME. The frequency and significance of small (less than or equal to 15 mm) hepatic lesions detected by CT. AJR Am J Roentgenol 1992; 158: 535-539
89. Konopke R, Kersting S, Saeger HD, Bunk A. [Detection of liver lesions by contrast-enhanced ultrasound - comparison to intraoperative findings] Ultraschall Med 2005; 26: 107-113
90. Soyer P, Levesque M, Caudron C, Elias D, Zeitoun G, Roche A. MRI of liver metastases from colorectal cancer vs. CT during arterial portography. J Comput Assist Tomogr 1993; 17: 67-74
91. Valls C, Andia E, Sanchez A, Guma A, Figueras J, Torras J, Serrano T. Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT. Radiology 2001; 218: 55-60
92. Ward J, Naik KS, Guthrie JA, Wilson D, Robinson PJ. Hepatic lesion detection: comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis. Radiology 1999; 210: 459-466
93. Dietrich CF. Characterisation of benign liver lesions with contrast-enhanced ultrasound. In: Lencioni R. Enhancing the role of ultrasound with ultrasound contrast agents. Pisa: Springer, 2006: 3-14
94. Terayama N, Matsui O, Ueda K, Kobayashi S, Sanada J, Gabata T, Kawamori Y, Kadoya M. Peritumoral rim enhancement of liver metastasis: hemodynamics observed on single-level dynamic CT during hepatic arteriography and histopathologic correlation. J Comput Assist Tomogr 2002; 26: 975-980
95. Paulson EK, McDermott VG, Keogan MT, DeLong DM, Frederick MG, Nelson RC. Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology 1998; 206: 143-150
96. Vogl TJ, Schwarz W, Blume S, Pietsch M, Shamsi K, Franz M, Lobeck H, Balzer T, del Tredici K, Neuhaus P, Felix R, Hammerstingl RM. Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US. Eur Radiol 2003; 13: 262-272
97. Kim MJ, Kim JH, Chung JJ, Park MS, Lim JS, Oh YT. Focal hepatic lesions: detection and characterization with combination gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. Radiology 2003; 228: 719-726
98. Kruskal JB, Kane RA. Intraoperative ultrasonography of the liver. Crit Rev Diagn Imaging 1995; 36: 175-226
99. Silas AM, Kruskal JB, Kane RA. Intraoperative ultrasound. Radiol Clin North Am 2001; 39: 429-448
100. Cervone A, Sardi A, Conaway GL. Intraoperative ultrasound (IOUS) is essential in the management of metastatic colorectal liver lesions. Am Surg 2000; 66: 611-615
101. Solomon MJ, Stephen MS, Gallinger S, White GH. Does intraoperative hepatic ultrasonography change surgical decision making during liver resection? Am J Surg 1994; 168: 307-310
102. Kane RA, Hughes LA, Cua EJ, Steele GD, Jenkins RL, Cady B. The impact of intraoperative ultrasonography on surgery for liver neoplasms. J Ultrasound Med 1994; 13: 1-6
103. Kruskal JB, Kane RA. Intraoperative US of the liver: techniques and clinical applications. Radiographics 2006; 26: 1067-1084